Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 573

1.

Author Correction: Lineage-specific RUNX2 super-enhancer activates MYC and promotes the development of blastic plasmacytoid dendritic cell neoplasm.

Kubota S, Tokunaga K, Umezu T, Yokomizo-Nakano T, Sun Y, Oshima M, Tan KT, Yang H, Kanai A, Iwanaga E, Asou N, Maeda T, Nakagata N, Iwama A, Ohyashiki K, Osato M, Sashida G.

Nat Commun. 2019 Aug 28;10(1):3943. doi: 10.1038/s41467-019-11919-x.

2.

A unique breast involvement detected by MRI-DWIBS in T cell acute lymphoblastic leukemia.

Katagiri S, Azuma K, Akahane D, Saito K, Ohyashiki K.

Breast J. 2019 Jul 12. doi: 10.1111/tbj.13457. [Epub ahead of print] No abstract available.

PMID:
31301079
3.

A novel non-invasive monitoring assay of 5-azacitidine efficacy using global DNA methylation of peripheral blood in myelodysplastic syndrome.

Asano M, Ohyashiki JH, Kobayashi-Kawana C, Umezu T, Imanishi S, Azuma K, Akahane D, Fujimoto H, Ito Y, Ohyashiki K.

Drug Des Devel Ther. 2019 May 30;13:1821-1833. doi: 10.2147/DDDT.S195071. eCollection 2019.

4.

Lineage-specific RUNX2 super-enhancer activates MYC and promotes the development of blastic plasmacytoid dendritic cell neoplasm.

Kubota S, Tokunaga K, Umezu T, Yokomizo-Nakano T, Sun Y, Oshima M, Tan KT, Yang H, Kanai A, Iwanaga E, Asou N, Maeda T, Nakagata N, Iwama A, Ohyashiki K, Osato M, Sashida G.

Nat Commun. 2019 Apr 10;10(1):1653. doi: 10.1038/s41467-019-09710-z. Erratum in: Nat Commun. 2019 Aug 28;10(1):3943.

5.

Maintenance 5-azacytidine therapy by MRD monitoring after allogeneic HSCT in myeloid/lymphoid neoplasms with FGFR1 rearrangement.

Katagiri S, Umezu T, Azuma K, Kobayashi C, Akahane D, Suguro T, Furuya N, Fujimoto H, Nakamura N, Ohyashiki JH, Ohyashiki K.

Bone Marrow Transplant. 2019 Jul;54(7):1148-1150. doi: 10.1038/s41409-019-0436-1. Epub 2019 Jan 22. No abstract available.

PMID:
30670826
6.

BIM deletion polymorphism accounts for lack of favorable outcome in Japanese females with follicular lymphoma.

Ito Y, Umezu T, Tadokoro K, Saito Y, Katagiri S, Suguro T, Asano M, Yoshizawa S, Akahane D, Tanaka Y, Fujimoto H, Okabe S, Gotoh M, Tauchi T, Kawana C, Ohyashiki JH, Nakamura N, Ohyashiki K.

Leuk Lymphoma. 2019 May;60(5):1283-1288. doi: 10.1080/10428194.2018.1529310. Epub 2018 Nov 27.

PMID:
30480474
7.

Copanlisib, a novel phosphoinositide 3-kinase inhibitor, combined with carfilzomib inhibits multiple myeloma cell proliferation.

Okabe S, Tanaka Y, Tauchi T, Ohyashiki K.

Ann Hematol. 2019 Mar;98(3):723-733. doi: 10.1007/s00277-018-3547-7. Epub 2018 Nov 15.

PMID:
30430191
8.

Chromatin Regulation by HP1γ Contributes to Survival of 5-Azacytidine-Resistant Cells.

Imanishi S, Umezu T, Kobayashi C, Ohta T, Ohyashiki K, Ohyashiki JH.

Front Pharmacol. 2018 Oct 16;9:1166. doi: 10.3389/fphar.2018.01166. eCollection 2018.

9.

Clonal architecture in patients with myelodysplastic syndromes and double or minor complex abnormalities: Detailed analysis of clonal composition, involved abnormalities, and prognostic significance.

Schanz J, Solé F, Mallo M, Luño E, Cervera J, Granada I, Hildebrandt B, Slovak ML, Ohyashiki K, Fonatsch C, Pfeilstöcker M, Nösslinger T, Valent P, Giagounidis A, Aul C, Lübbert M, Stauder R, Krieger O, Le Beau MM, Bennett JM, Greenberg P, Germing U, Haase D.

Genes Chromosomes Cancer. 2018 Nov;57(11):547-556. doi: 10.1002/gcc.22667. Epub 2018 Sep 24.

PMID:
30248204
10.

Cardiac biopsy with intracardiac echocardiographic guidance for successful diagnosis of cardiac lymphoma.

Katagiri S, Akahane D, Suguro T, Furuya N, Fujimoto H, Saito T, Yamashita J, Nakamura N, Ohyashiki K.

Clin Case Rep. 2018 Jul 9;6(9):1681-1683. doi: 10.1002/ccr3.1699. eCollection 2018 Sep.

11.

Therapeutic targeting of Aurora A kinase in Philadelphia chromosome-positive ABL tyrosine kinase inhibitor-resistant cells.

Okabe S, Tauchi T, Tanaka Y, Ohyashiki K.

Oncotarget. 2018 Aug 21;9(65):32496-32506. doi: 10.18632/oncotarget.25985. eCollection 2018 Aug 21.

12.

Exosomal miRNA Signatures for Late-Onset Acute Graft-Versus-Host Disease in Allogenic Hematopoietic Stem Cell Transplantation.

Yoshizawa S, Umezu T, Saitoh Y, Gotoh M, Akahane D, Kobayashi C, Ohyashiki JH, Ohyashiki K.

Int J Mol Sci. 2018 Aug 23;19(9). pii: E2493. doi: 10.3390/ijms19092493.

13.

HIV positivity may not have a negative impact on survival in Epstein-Barr virus-positive Hodgkin lymphoma: A Japanese nationwide retrospective survey.

Yotsumoto M, Ito Y, Hagiwara S, Terui Y, Nagai H, Ota Y, Ajisawa A, Uehira T, Tanuma J, Ohyashiki K, Okada S.

Oncol Lett. 2018 Sep;16(3):3923-3928. doi: 10.3892/ol.2018.9132. Epub 2018 Jul 11.

14.

R-High-CHOP/CHASER/LEED with autologous stem cell transplantation in newly diagnosed mantle cell lymphoma: JCOG0406 STUDY.

Ogura M, Yamamoto K, Morishima Y, Wakabayashi M, Tobinai K, Ando K, Uike N, Kurosawa M, Gomyo H, Taniwaki M, Nosaka K, Tsukamoto N, Shimoyama T, Fukuhara N, Yakushijin Y, Ohnishi K, Miyazaki K, Sawada K, Takayama N, Hanamura I, Nagai H, Kobayashi H, Usuki K, Kobayashi N, Ohyashiki K, Utsumi T, Kumagai K, Maruyama D, Ohmachi K, Matsuno Y, Nakamura S, Hotta T, Tsukasaki K; Japan Clinical Oncology Group- Lymphoma Study Group (JCOG-LSG).

Cancer Sci. 2018 Sep;109(9):2830-2840. doi: 10.1111/cas.13719. Epub 2018 Jul 28.

15.

[Human herpesvirus-6 pneumonitis following autologous peripheral blood stem cell transplantation].

Saitoh Y, Gotoh M, Yoshizawa S, Akahane D, Fujimoto H, Ito Y, Ohyashiki K.

Rinsho Ketsueki. 2018;59(3):300-304. doi: 10.11406/rinketsu.59.300. Japanese.

PMID:
29618688
16.

Regulatory T cell inhibition by dasatinib is associated with natural killer cell differentiation and a favorable molecular response-The final results of the D-first study.

Najima Y, Yoshida C, Iriyama N, Fujisawa S, Wakita H, Chiba S, Okamoto S, Kawakami K, Takezako N, Kumagai T, Ohyashiki K, Taguchi J, Yano S, Igarashi T, Kouzai Y, Morita S, Sakamoto J, Sakamaki H, Inokuchi K.

Leuk Res. 2018 Mar;66:66-72. doi: 10.1016/j.leukres.2018.01.010. Epub 2018 Feb 3.

PMID:
29407585
17.

Therapeutic effects of tyrosine kinase inhibitors and subtypes of BCR-ABL1 transcripts in Japanese chronic myeloid leukemia patients with three-way chromosomal translocations.

Inokuchi K, Nakayama K, Tauchi T, Takaku T, Yokose N, Yamaguchi H, Kumagai T, Komatsu N, Ohyashiki K.

Leuk Res. 2018 Feb;65:74-79. doi: 10.1016/j.leukres.2018.01.005. Epub 2018 Jan 3.

PMID:
29310021
18.

Replenishing exosomes from older bone marrow stromal cells with miR-340 inhibits myeloma-related angiogenesis.

Umezu T, Imanishi S, Azuma K, Kobayashi C, Yoshizawa S, Ohyashiki K, Ohyashiki JH.

Blood Adv. 2017 May 16;1(13):812-823. doi: 10.1182/bloodadvances.2016003251. eCollection 2017 May 23.

19.

Extracellular vesicle-mediated cell-cell communication in haematological neoplasms.

Ohyashiki JH, Umezu T, Ohyashiki K.

Philos Trans R Soc Lond B Biol Sci. 2018 Jan 5;373(1737). pii: 20160484. doi: 10.1098/rstb.2016.0484. Review.

20.

Teriflunomide restores 5-azacytidine sensitivity via activation of pyrimidine salvage in 5-azacytidine-resistant leukemia cells.

Imanishi S, Takahashi R, Katagiri S, Kobayashi C, Umezu T, Ohyashiki K, Ohyashiki JH.

Oncotarget. 2017 Jul 22;8(41):69906-69915. doi: 10.18632/oncotarget.19436. eCollection 2017 Sep 19.

21.

Hidden FLT3-D835Y clone in FLT3-ITD-positive acute myeloid leukemia that evolved into very late relapse with T-lymphoblastic leukemia.

Katagiri S, Umezu T, Azuma K, Asano M, Akahane D, Makishima H, Yoshida K, Watatani Y, Chiba K, Miyano S, Ogawa S, Ohyashiki JH, Ohyashiki K.

Leuk Lymphoma. 2018 Jun;59(6):1490-1493. doi: 10.1080/10428194.2017.1382696. Epub 2017 Oct 3. No abstract available.

PMID:
28972800
22.

Genetic variations of bone marrow mesenchymal stromal cells derived from acute leukemia and myelodysplastic syndrome by targeted deep sequencing.

Azuma K, Umezu T, Imanishi S, Asano M, Yoshizawa S, Katagiri S, Ohyashiki K, Ohyashiki JH.

Leuk Res. 2017 Nov;62:23-28. doi: 10.1016/j.leukres.2017.09.008. Epub 2017 Sep 21.

PMID:
28964959
23.

Phase 1/2 study of the WT1 peptide cancer vaccine WT4869 in patients with myelodysplastic syndrome.

Ueda Y, Ogura M, Miyakoshi S, Suzuki T, Heike Y, Tagashira S, Tsuchiya S, Ohyashiki K, Miyazaki Y.

Cancer Sci. 2017 Dec;108(12):2445-2453. doi: 10.1111/cas.13409. Epub 2017 Oct 25.

24.

Amyloid Angiopathy-related Severe Hemorrhage with Multiple Myeloma.

Katagiri S, Akahane D, Tanaka Y, Ohyashiki K.

Intern Med. 2017 Nov 1;56(21):2957-2958. doi: 10.2169/internalmedicine.8609-16. Epub 2017 Sep 25. No abstract available.

25.

Unique radiological features of two cases of primary pulmonary diffuse large B-cell lymphoma.

Saitoh Y, Ohnishi-Amemiya A, Asano M, Tanaka Y, Yoshizawa S, Fujimoto H, Itoh Y, Nakamura N, Ohyashiki K.

Thorax. 2017 Sep;72(9):859-860. doi: 10.1136/thoraxjnl-2017-210248. Epub 2017 Jul 14. No abstract available.

PMID:
28710338
26.

Targeting peroxisome proliferator-activated receptors: a novel strategy for Philadelphia chromosome-positive leukemia cells.

Okabe S, Tauchi T, Tanaka Y, Ohyashiki K.

Leuk Lymphoma. 2017 Nov;58(11):2762-2764. doi: 10.1080/10428194.2017.1312373. Epub 2017 May 15. No abstract available.

PMID:
28504032
27.

BCR-ABL1-positive chronic myeloid leukemia emerging in a patient with secondary myelofibrosis harboring the JAK2-V617F mutation.

Amemiya A, Ito Y, Ishibashi Y, Saito Y, Katagiri S, Suguro T, Asano M, Yoshizawa S, Akahane D, Tanaka Y, Fujimoto H, Okabe S, Gotoh M, Tauchi T, Ohyashiki K.

Rinsho Ketsueki. 2017;58(4):298-302. doi: 10.11406/rinketsu.58.298. Japanese.

PMID:
28484156
28.

Low body weight and body mass index may be associated with musculoskeletal pain following imatinib discontinuation in chronic myeloid leukemia.

Katagiri S, Tauchi T, Ando K, Okabe S, Gotoh M, Ohyashiki K.

Leuk Res Rep. 2017 Apr 12;7:33-35. doi: 10.1016/j.lrr.2017.04.002. eCollection 2017.

29.

Ponatinib in Japanese patients with Philadelphia chromosome-positive leukemia, a phase 1/2 study.

Tojo A, Kyo T, Yamamoto K, Nakamae H, Takahashi N, Kobayashi Y, Tauchi T, Okamoto S, Miyamura K, Hatake K, Iwasaki H, Matsumura I, Usui N, Naoe T, Tugnait M, Narasimhan NI, Lustgarten S, Farin H, Haluska F, Ohyashiki K.

Int J Hematol. 2017 Sep;106(3):385-397. doi: 10.1007/s12185-017-2238-9. Epub 2017 Apr 25.

PMID:
28444644
30.

Up-regulated exosomal miRNA-140-3p in CML patients with musculoskeletal pain associated with discontinuation of tyrosine kinase inhibitors.

Asano M, Umezu T, Katagiri S, Kobayashi C, Tauchi T, Gotoh M, Ando K, Okabe S, Ohyashiki JH, Ohyashiki K.

Int J Hematol. 2017 Apr;105(4):419-422. doi: 10.1007/s12185-017-2199-z. Epub 2017 Feb 14.

PMID:
28197964
31.

Erratum to: Assessing the safety and efficacy of ruxolitinib in a multicenter, open-label study in Japanese patients with myelofibrosis.

Komatsu N, Kirito K, Shimoda K, Ishikawa T, Ohishi K, Ohyashiki K, Takahashi N, Okada H, Amagasaki T, Yonezu T, Akashi K.

Int J Hematol. 2017 Mar;105(3):387. doi: 10.1007/s12185-017-2196-2. No abstract available.

PMID:
28176224
32.

Poly (ADP-ribose) polymerase inhibitors selectively induce cytotoxicity in TCF3-HLF-positive leukemic cells.

Piao J, Takai S, Kamiya T, Inukai T, Sugita K, Ohyashiki K, Delia D, Masutani M, Mizutani S, Takagi M.

Cancer Lett. 2017 Feb 1;386:131-140. doi: 10.1016/j.canlet.2016.11.021. Epub 2016 Nov 25.

PMID:
27894958
33.

Assessing the safety and efficacy of ruxolitinib in a multicenter, open-label study in Japanese patients with myelofibrosis.

Komatsu N, Kirito K, Shimoda K, Ishikawa T, Ohishi K, Ohyashiki K, Takahashi N, Okada H, Amagasaki T, Yonezu T, Akashi K.

Int J Hematol. 2017 Mar;105(3):309-317. doi: 10.1007/s12185-016-2130-z. Epub 2016 Nov 10. Erratum in: Int J Hematol. 2017 Mar;105(3):387.

PMID:
27832516
34.

Switching to nilotinib in patients with chronic myeloid leukemia in chronic phase with molecular suboptimal response to frontline imatinib: SENSOR final results and BIM polymorphism substudy.

Miyamura K, Miyamoto T, Tanimoto M, Yamamoto K, Kimura S, Kawaguchi T, Matsumura I, Hata T, Tsurumi H, Saito S, Hino M, Tadokoro S, Meguro K, Hyodo H, Yamamoto M, Kubo K, Tsukada J, Kondo M, Aoki M, Okada H, Yanada M, Ohyashiki K, Taniwaki M.

Leuk Res. 2016 Dec;51:11-18. doi: 10.1016/j.leukres.2016.09.009. Epub 2016 Sep 5.

PMID:
27771544
35.

Association of pleural effusion with an early molecular response in patients with newly diagnosed chronic-phase chronic myeloid leukemia receiving dasatinib: Results of a D-First study.

Hagihara M, Iriyama N, Yoshida C, Wakita H, Chiba S, Okamoto S, Kawakami K, Takezako N, Kumagai T, Inokuchi K, Ohyashiki K, Taguchi J, Yano S, Igarashi T, Kouzai Y, Morita S, Sakamoto J, Sakamaki H.

Oncol Rep. 2016 Nov;36(5):2976-2982. doi: 10.3892/or.2016.5110. Epub 2016 Sep 20.

PMID:
27665844
36.

Interim analysis of post-marketing surveillance of eculizumab for paroxysmal nocturnal hemoglobinuria in Japan.

Ninomiya H, Obara N, Chiba S, Usuki K, Nishiwaki K, Matsumura I, Shichishima T, Okamoto S, Nishimura JI, Ohyashiki K, Nakao S, Ando K, Kanda Y, Kawaguchi T, Nakakuma H, Harada D, Akiyama H, Kinoshita T, Ozawa K, Omine M, Kanakura Y.

Int J Hematol. 2016 Nov;104(5):548-558. Epub 2016 Jul 27.

PMID:
27464489
37.

Long-term remission of acquired von Willebrand syndrome associated with multiple myeloma using bortezomib and dexamethasone therapy.

Katagiri S, Akahane D, Amano K, Ohyashiki K.

Haemophilia. 2016 Nov;22(6):e557-e559. doi: 10.1111/hae.13077. Epub 2016 Sep 19. No abstract available.

PMID:
27641423
38.

Musculoskeletal pain after stopping tyrosine kinase inhibitor in patients with chronic myeloid leukemia: a questionnaire survey.

Katagiri S, Tauchi T, Saito Y, Suguro T, Asano M, Yoshizawa S, Sakuta J, Akahane D, Tanaka Y, Furuya N, Ando K, Fujimoto H, Okabe S, Gotoh M, Ito Y, Ohyashiki K.

Rinsho Ketsueki. 2016 Jul;57(7):873-6. doi: 10.11406/rinketsu.57.873. Japanese.

PMID:
27498732
39.

Combination therapy with copanlisib and ABL tyrosine kinase inhibitors against Philadelphia chromosome-positive resistant cells.

Okabe S, Tauchi T, Tanaka Y, Sakuta J, Ohyashiki K.

Oncotarget. 2016 Aug 16;7(33):53116-53126. doi: 10.18632/oncotarget.10605.

40.

Downregulation of Plasma miR-215 in Chronic Myeloid Leukemia Patients with Successful Discontinuation of Imatinib.

Ohyashiki K, Umezu T, Katagiri S, Kobayashi C, Azuma K, Tauchi T, Okabe S, Fukuoka Y, Ohyashiki JH.

Int J Mol Sci. 2016 Apr 15;17(4):570. doi: 10.3390/ijms17040570.

41.

Fatal Cyberlindnera fabianii fungemia in a patient with mixed phenotype acute leukemia after umbilical cord blood transplantation.

Katagiri S, Gotoh M, Tone K, Akahane D, Ito Y, Ohyashiki K, Makimura K.

Int J Hematol. 2016 May;103(5):592-5. doi: 10.1007/s12185-016-1953-y. Epub 2016 Feb 15.

PMID:
26879198
42.

Exosomes promote bone marrow angiogenesis in hematologic neoplasia: the role of hypoxia.

Ohyashiki JH, Umezu T, Ohyashiki K.

Curr Opin Hematol. 2016 May;23(3):268-73. doi: 10.1097/MOH.0000000000000235. Review.

PMID:
26866730
43.

Frequency of del(12p) is commonly underestimated in myelodysplastic syndromes: Results from a German diagnostic study in comparison with an international control group.

Braulke F, Müller-Thomas C, Götze K, Platzbecker U, Germing U, Hofmann WK, Giagounidis AA, Lübbert M, Greenberg PL, Bennett JM, Solé F, Slovak ML, Ohyashiki K, Le Beau MM, Tüchler H, Pfeilstöcker M, Hildebrandt B, Aul C, Stauder R, Valent P, Fonatsch C, Bacher U, Trümper L, Haase D, Schanz J.

Genes Chromosomes Cancer. 2015 Dec;54(12):809-17. doi: 10.1002/gcc.22292. Epub 2015 Sep 10.

PMID:
26355708
44.

Anti-leukemic activity of axitinib against cells harboring the BCR-ABL T315I point mutation.

Okabe S, Tauchi T, Tanaka Y, Sakuta J, Ohyashiki K.

J Hematol Oncol. 2015 Aug 4;8:97. doi: 10.1186/s13045-015-0190-9.

45.

Early cytotoxic lymphocyte expansion contributes to a deep molecular response to dasatinib in patients with newly diagnosed chronic myeloid leukemia in the chronic phase: results of the D-first study.

Iriyama N, Fujisawa S, Yoshida C, Wakita H, Chiba S, Okamoto S, Kawakami K, Takezako N, Kumagai T, Inokuchi K, Ohyashiki K, Taguchi J, Yano S, Igarashi T, Kouzai Y, Morita S, Sakamoto J, Sakamaki H.

Am J Hematol. 2015 Sep;90(9):819-24. doi: 10.1002/ajh.24096.

46.

Effect of combined deferasirox and 5-azacytidine treatment on human leukemia cells in vitro.

Imanishi S, Takahashi R, Ohsuga M, Ohyashiki K, Ohyashiki JH.

Ann Hematol. 2015 Sep;94(9):1601-2. doi: 10.1007/s00277-015-2417-9. Epub 2015 Jun 6. No abstract available.

PMID:
26044890
48.

[Treatment-free molecular remission achieved by combination therapy with imatinib and IFNα in CML with BIM deletion polymorphism relapsed after stop imatinib].

Katagiri S, Tauchi T, Umezu T, Saito Y, Suguro T, Asano M, Yoshizawa S, Kitahara T, Akahane D, Tanaka Y, Fujimoto H, Okabe S, Gotoh M, Ito Y, Ohyashiki JH, Ohyashiki K.

Rinsho Ketsueki. 2015 Feb;56(2):216-9. doi: 10.11406/rinketsu.56.216. Japanese.

PMID:
25765803
49.

Shorter halving time of BCR-ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic-phase chronic myeloid leukemia treated with dasatinib: Results of the D-first study of Kanto CML study group.

Iriyama N, Fujisawa S, Yoshida C, Wakita H, Chiba S, Okamoto S, Kawakami K, Takezako N, Kumagai T, Inokuchi K, Ohyashiki K, Taguchi J, Yano S, Igarashi T, Kouzai Y, Morita S, Sakamoto J, Sakamaki H.

Am J Hematol. 2015 Apr;90(4):282-7. doi: 10.1002/ajh.23923. Epub 2015 Mar 2.

50.

Validation of cytogenetic risk groups according to International Prognostic Scoring Systems by peripheral blood CD34+FISH: results from a German diagnostic study in comparison with an international control group.

Braulke F, Platzbecker U, Müller-Thomas C, Götze K, Germing U, Brümmendorf TH, Nolte F, Hofmann WK, Giagounidis AA, Lübbert M, Greenberg PL, Bennett JM, Solé F, Mallo M, Slovak ML, Ohyashiki K, Le Beau MM, Tüchler H, Pfeilstöcker M, Nösslinger T, Hildebrandt B, Shirneshan K, Aul C, Stauder R, Sperr WR, Valent P, Fonatsch C, Trümper L, Haase D, Schanz J.

Haematologica. 2015 Feb;100(2):205-13. doi: 10.3324/haematol.2014.110452. Epub 2014 Oct 24.

Supplemental Content

Loading ...
Support Center